Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
05/2001
05/17/2001WO2001034629A1 21 human secreted proteins
05/17/2001WO2001034628A1 35 human secreted proteins
05/17/2001WO2001034627A1 28 human secreted proteins
05/17/2001WO2001034623A1 29 human secreted proteins
05/17/2001WO2001034614A2 Compositions and methods for double-targeting virus infections and targeting cancer cells
05/17/2001WO2001034610A1 Polycycloalkylpurines as adenosine receptor antagonists
05/17/2001WO2001034608A1 Hydromorphinone and hydrocodeinone compositions and methods for their synthesis
05/17/2001WO2001034607A1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
05/17/2001WO2001034605A1 SUBSTITUTED 2-ARYL-3-(HETEROARYL)-IMIDAZO[1,2-a]PYRIMIDINES, AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS
05/17/2001WO2001034604A2 Adenosine receptor antagonists and methods of making and using the same
05/17/2001WO2001034603A2 Bicyclic and tricyclic heteroaromatic compounds
05/17/2001WO2001034601A2 Imidazopyridine derivatives as phosphodiesterase vii inhibitors
05/17/2001WO2001034598A1 [(indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
05/17/2001WO2001034597A1 N-aryl-(homopiperazinyl)-cyclohexyl amines as 5-ht transporters
05/17/2001WO2001034594A1 Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
05/17/2001WO2001034593A1 Compound with growth hormone releasing properties
05/17/2001WO2001034586A2 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht1a activity
05/17/2001WO2001034571A1 β-AMINOACID COMPOUNDS USEFUL FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS
05/17/2001WO2001034562A1 Aralkyl-1,2-diamines having calcimimetic activity and preparation mode
05/17/2001WO2001034225A2 Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith
05/17/2001WO2001034201A2 Methods for inhibiting neurofibromatosis type 1 (nf1)
05/17/2001WO2001034183A2 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
05/17/2001WO2001034178A2 Methods and compositions for treatment of traumatic brain injury
05/17/2001WO2001034167A1 Isolation and expansion of human marrow stromal cells
05/17/2001WO2001034166A1 Transplant/implant device and method for its production
05/17/2001WO2001034165A1 Therapeutic compositions and methods of use thereof
05/17/2001WO2001034161A1 A method of treating substance addiction
05/17/2001WO2001034141A1 Il-8 receptor antagonists
05/17/2001WO2001034138A1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
05/17/2001WO2001034136A2 Use of adatanserin for the treatment of neurodegenerative conditions
05/17/2001WO2001034125A2 Therapeutic use and formulation of (-)-tramadol
05/17/2001WO2001034120A1 Apparatus and method for preparing microparticles using in-line solvent extraction
05/17/2001WO2001034113A2 Apparatus and method for preparing microparticles
05/17/2001WO2001034095A2 A method for treating viral diseases and other disorders by altering immediate gene expression through administration of peptide t
05/17/2001WO2001033942A1 Method for producing metabolites from plants cultivated in soil-less medium
05/17/2001WO2001018043A3 Neurogenic compositions and methods
05/17/2001WO2001012598A9 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF
05/17/2001WO2001009116A3 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE
05/17/2001WO2001007471A9 Cell cycle and proliferation proteins
05/17/2001WO2001005390A3 Method for treating chronic pain using mek inhibitors
05/17/2001WO2001004157A3 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS
05/17/2001WO2001003648A3 Oregano-based therapeutic composition
05/17/2001WO2001001973A8 Highly selective norepinephrine reuptake inhibitors and methods of using the same
05/17/2001WO2000049137B1 Pluripotential cell derived from an embryonic stem cell and a nucleus of a somatic cell
05/17/2001WO2000041484A3 Novel use of phospholipids of vegetable and animal origin in nutritional therapy
05/17/2001DE19954707A1 Imidazolverbindungen als Phosphodiesterase VII-Hemmer Imidazole compounds as phosphodiesterase VII inhibitor
05/17/2001DE19953339A1 Secretinfragmente Secretinfragmente
05/17/2001CA2854796A1 Hydromorphinone and hydrocodeinone compositions and methods for their synthesis
05/17/2001CA2428827A1 Human vanilloid receptor gene
05/17/2001CA2391278A1 Therapeutic compositions and methods of use thereof
05/17/2001CA2390880A1 Aralkyl-1,2-diamines having calcimimetic activity and preparation mode
05/17/2001CA2390834A1 Transplant/implant device and method for its production
05/17/2001CA2390797A1 Methods for the treatment and prevention of neurodegenerative conditions
05/17/2001CA2390655A1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
05/17/2001CA2390531A1 ¬(indol-3-yl)-cycloalkyl|-3-substituted azetidines for the treatment of central nervous system disorders
05/17/2001CA2390530A1 N-aryl-(homopiperazinyl)-cyclohexyl amines as 5-ht transporters
05/17/2001CA2390524A1 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht1a activity
05/17/2001CA2390510A1 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
05/17/2001CA2390496A1 Polycycloalkylpurines as adenosine receptor antagonists
05/17/2001CA2390438A1 19 human secreted proteins
05/17/2001CA2390421A1 24 human secreted proteins
05/17/2001CA2390376A1 .beta.-aminoacid compounds useful for inhibiting .beta.-amyloid peptide release and/or its synthesis
05/17/2001CA2390231A1 Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
05/17/2001CA2390161A1 Methods for identifying and using amyloid-inhibitory compounds
05/17/2001CA2390101A1 A method of treating substance addiction
05/17/2001CA2389724A1 28 human secreted proteins
05/17/2001CA2389722A1 15 human secreted proteins
05/17/2001CA2389488A1 Isolation and expansion of human marrow stromal cells
05/17/2001CA2389392A1 A method for treating viral diseases and other disorders by altering immediate gene expression through administration of peptide t
05/17/2001CA2389326A1 35 human secreted proteins
05/17/2001CA2389193A1 Hydromorphone compositions and methods of their synthesis
05/17/2001CA2389041A1 Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or .beta.-sheet rich pathological precursor thereof
05/17/2001CA2388912A1 6 human secreted proteins
05/17/2001CA2388750A1 .beta.-aminoacid compounds useful for inhibiting .beta.-amyloid peptide release and/or its synthesis
05/17/2001CA2388729A1 Imidazopyridine derivatives as phosphodiesterase vii inhibitors
05/17/2001CA2388644A1 Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith
05/17/2001CA2388593A1 Bicyclic and tricyclic heteroaromatic compounds
05/17/2001CA2388343A1 Methods for inhibiting neurofibromatosis type 1 (nf1)
05/17/2001CA2388019A1 24 human secreted proteins
05/17/2001CA2388008A1 29 human secreted proteins
05/17/2001CA2387964A1 22 human secreted proteins
05/17/2001CA2387959A1 21 human secreted proteins
05/17/2001CA2387624A1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
05/17/2001CA2361139A1 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods
05/17/2001CA2359955A1 Human vanilloid receptor gene
05/16/2001EP1099702A1 Substituted morpholine derivatives and their use as therapeutic agents
05/16/2001EP1099692A1 N,n-substituted cyclic amine derivatives
05/16/2001EP1099446A2 Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent
05/16/2001EP1099445A2 Treatment of neuromuscular disorders and conditions with different botulinum serotype
05/16/2001EP1099443A1 Transplant/implant device and method for its production
05/16/2001EP1098985A1 Genes of the dead box protein family, their expression products and use
05/16/2001EP1098978A1 Gbs toxin receptor
05/16/2001EP1098970A1 Human sbpsapl gene with homology to the prosaposin family of neurotrophic factors
05/16/2001EP1098906A1 Peptide analogues of pacap
05/16/2001EP1098897A1 Compounds, compositions, and methods for stimulating neuronal growth and elongation
05/16/2001EP1098896A1 5-bicycloindole compounds
05/16/2001EP1098894A1 Fkbp inhibitors
05/16/2001EP1098892A1 Biphenyl derivatives
05/16/2001EP1098884A1 Il-8 receptor antagonists
05/16/2001EP1098871A1 $g(a)-AMINO ACID PHENYL ESTER DERIVATIVES